Antibe Therapeutics completes patient enrollment in OA knee pain trial for ATB-346
Antibe Therapeutics, a Canadian pharma company has completed enrollment of patients in a phase 2B dose-ranging, efficacy clinical trial of its lead drug candidate ATB-346 for its use in reducing osteoarthritis (OA) pain. The mid-stage clinical study will assess the effectiveness of ATB-346 in the reduction of OA knee pain in comparison to placebo in […]